Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Lurasidone for cognitive functioning in euthymic bipolar disorder
NCT02731612Phase 3Completed
- Start
- May 2017
- Primary completion
- Dec 2024
- Modality
- Small Molecules
- Countries
- 4
01
Overview
Phase 3, randomised, double-blind trial in bipolar disorder (BD) comparing Lurasidone with Placebo (2 arms). Primary endpoint: Improvement in cognitive performance at 6 weeks. Started May 2017; status: completed.
02
Drugs
lurasidone
03
Conditions
bipolar disorder (BD)
Beyond the preview
Go deeper on NCT02731612.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02731612.